Skip to main content
. Author manuscript; available in PMC: 2013 Jul 29.
Published in final edited form as: Cancer. 2012 May 8;118(21):5403–5413. doi: 10.1002/cncr.27526

Figure 6.

Figure 6

Tumor marker expression levels are shown. Percentage of positive cells in archival or pretherapy biopsy specimens of study patients are determined by immunohistochemical analysis. For each marker, patients who benefited from therapy (stable disease for >60 days or partial response) are compared with those who did not. These analyses are intended to be exploratory and hypothesis-generating only, and the P values are not adjusted for multiple statistical comparisons. AKT, protein kinase B; ERK, extracellular signal-regulated kinase; PPAR, peroxisome proliferator-activated receptor; PTEN, phosphatase and tensin homologue; RXR, retinoid-X receptor; p, phosphorylated.